CNS Biotechnology specialises in research and development of new products and the reformulation of existing products, for the natural health industry.
High levels of UV sunlight in New Zealand has been shown to elevate levels of biologically active phytonutrients in fruits, vegetables and edible plants, which makes these produces demonstrably healthier. It is the unique growing environment found only in New Zealand, which is why CNS Biotechnology is able to develop such novel, biologically active ingredients.
- abdominal (central) obesity
- elevated blood pressure
- elevated fasting plasma glucose
- high serum triglycerides
- Low levels of high-density lipoprotein (HDL)
A growing number of consumers suffering from metabolic syndrome are at an increased risk of developing non-communicable chronic diseases such as diabetes, cardiovascular problems and cancer. The global diabetes prevalence is expected to rise to 4% to account for 9% of the 20-79 years old population in 2020. The highest prevalence rates are expected in North America (11%), Australasia (10%) and Western Europe (10%) according to Euromonitor International.
Our Advisory Group
Dr Jeremy Burton BSc, MSc, PhD, dBA.
Miriam Burnett Chair in Urological Sciences. Deputy Director of the Canadian Centre for Human Microbiome and Probiotics based in the Lawson Health Research Institute. He is an Assistant Professor in the Division of Urology, Department of Surgery and cross-appointed to the Department of Microbiology & Immunology at Western University.
After several years of undertaking studies with human probiotics for upper-respiratory-tract applications, Dr Burton returned to the Lawson Health Research Institute and the Canadian Research and Development Centre for Probiotics to continue working on the exciting area of translating microbial ecological research into real-world applications.
CNS Biotechnology is delighted to have Dr Burton advising on innovative health and nutrition.